Work Here?
About Tarsus Pharamceuticals
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Total Funding
$58.4M
Headquarters
Irvine, California
Founded
2017
Overview
Tarsus Pharmaceuticals develops treatments for diseases that lack effective solutions, focusing mainly on eye care and infectious diseases. Their key product, XDEMVY, is an FDA-approved eye drop solution used to treat Demodex Blepharitis, a condition affecting the eyelids. The company is also working on other potential treatments for conditions like Lyme Disease Prevention, Meibomian Gland Disease, and Rosacea. Tarsus differentiates itself from competitors by concentrating on specific medical needs and maintaining a strong pipeline of future products. Their goal is to provide effective treatments for patients suffering from these conditions while ensuring compliance with regulations and ethical standards.
Simplify's Take
What believers are saying
- Growing awareness of Demodex blepharitis expands market for Tarsus's XDEMVY.
- Telemedicine rise offers new marketing opportunities for Tarsus's products.
- FDA's focus on unmet needs may expedite Tarsus's pipeline approvals.
What critics are saying
- Increased competition in ophthalmic treatments challenges Tarsus's market position.
- Potential clinical trial delays could affect Tarsus's product pipeline.
- Supply chain constraints may hinder XDEMVY's production and distribution.
What makes Tarsus Pharamceuticals unique
- Tarsus focuses on high unmet needs in ophthalmic and infectious diseases.
- Their lead product, XDEMVY, is FDA-approved for Demodex blepharitis treatment.
- Tarsus's pipeline includes innovative treatments for Lyme disease and Rosacea.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$58.4M
Above
Industry Average
Funded Over
4 Rounds
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Paid Vacation
Hybrid Work Options
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 1%1 year growth
↑ 0%2 year growth
↑ 8%Mutual of America Capital Management LLC invests $4.29 million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS).
Tarsus welcomes Kate Goodrich, M.D., MHS, to its Board of Directors.
IRVINE, Calif.- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a company that applies proven science and new technology to eyecare to improve treatment for patients, has announced the appointment of Elizabeth Yeu, MD, as chief medical officer, effective November 4, 2024.
Meanwhile, Tarsus in April picked up $200 million in financing from Pharmakon Advisors, on top of the $180 million equity offering the company pulled off earlier in the year.
IRVINE, Calif., April 23, 2024 (GLOBE NEWSWIRE) - Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it has secured $200 million in committed capital from funds associated with Pharmakon Advisors, LP.
Tarsus Pharamceuticals is Hiring for 23 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Tarsus Pharamceuticals
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Total Funding
$58.4M
Headquarters
Irvine, California
Founded
2017
Tarsus Pharamceuticals is Hiring for 23 Jobs on Simplify!
Find jobs on Simplify and start your career today